Background and Objectives: The human Secretor α(1,2)fucosyltransferase gene determines the ABH secretor status and influences the Lewis phenotype of an individual. Studies were carried out on the Lewis (a+b–) nonsecretors of different groups indigenous to Taiwan to demonstrate their se genotypes. Methods: The Lewis phenotype of the blood samples was determined by a microplate method. The se genotypes of the individuals with the Lewis (a+b–) phenotype were analyzed by a polymerase chain reaction restriction fragment length polymorphism (PCR–RFLP) method designed for the se alleles reported previously. PCR and cloning techniques were used to determine the coding sequence of the novel se gene. Results: A new se allele, se685, with a three–nucleotide deletion of GTGGT to GT in the coding region of nucleotides 685 through 689 was identified in a Le (a+b–) nonsecretor from the Ami tribe indigenous to Taiwan. The deletion predicts the loss of the amino acid Val230 in the corresponding secretor enzyme's C–terminal segment. The distribution of the se685 allele in the Ami tribe was further verified by PCR–RFLP analysis. Conclusion: The Se gene exhibits heterogeneity with some Se alleles being common but others displaying a unique distribution in different ethnic populations. The newly identified se685 allele seems to exist only in the Ami tribe indigenous to Taiwan.

1.
Watkins WM: Biochemistry and genetics of the ABO, Lewis, and P blood group systems. Adv Hum Genet 1980;10:1–136.
2.
Henry S, Oriol R, Samuelsson B: Lewis histo–blood group system and associated secretor phenotypes. Vox Sang 1995;69:166–182.
3.
Rouquier S, Lowe JB, Kelly RJ, Fertitta AL, Lennon GG, Giorgi D: Molecular cloning of a human genomic region containing the H blood group α(1,2)fucosyltransferase gene and two H locus–related DNA restriction fragments. J Biol Chem 1995;270:4632–4639.
4.
Kelly RJ, Roquier S, Giorgi D, Lennon GG, Lowe JB: Sequence and expression of a candidate for the human Secretor blood group α(1,2)fucosyltransferase gene (FUT2). J Biol Chem 1995;270:4640–4649.
5.
Kukowska–Latallo JF, Larsen RD, Nair RP, Lowe JB: A cloned human cDNA determines expression of a mouse stage–specific embryonic antigen and the Lewis blood group α(1,3/1,4)fucosyltransferase. Genes Dev 1990; 4:1288–1303.
6.
Sturgeon P, Arcilla MB: Studies on the secretion of blood group substances. I. Observations on the red cell phenotype Le (a+b+x+). Vox Sang 1970;18:301–322.
7.
Oriol R, Danilovs J, Hawkins BR: A new genetic model proposing that the Se gene is a structural gene closely linked to the H gene. Am J Hum Genet 1981;33:421–431.
8.
Yu L–C, Yang Y–H, Broadberry RE, Chen Y–H, Chan Y–S, Lin M: Correlation of a missense mutation in the human Secretor α1,2–fucosyltransferase gene with the Lewis (a+b+) phenotype: A potential molecular basis for the weak Secretor allele (Sew). Biochem J 1995;312: 329–332.
9.
Henry S, Mollicone R, Fernandez P, Samuelsson B, Oriol R, Larson G: Homozygous expression of a missense mutation at nucleotide 385 in the FUT2 gene associated with the Le (a+b+) partial–secretor phenotype in an Indonesian family. Biochem Biophys Res Commun 1996;219:675–678.
10.
Henry S, Mollicone R, Fernandez P, Samuelsson B, Oriol R, Larson G: Molecular basis for erythrocyte Le (a+b+) and salivary ABH partial–secretor phenotypes. Expression of a FUT2 secretor allele with an A→T mutation at nucleotide 385 correlates with reduced α(1,2)fucosyltransferase activity. Glycoconj J 1996;13:985–993.
11.
Braodberry RE, Lin–Chu M: The Lewis blood group system among Chinese in Taiwan. Hum Hered 1991;41:290–294.
12.
Broadberry RE, Lin M: Comparison of the Lewis phenotype among the different population groups of Taiwan. Transfus Med 1996;6: 255–260.
13.
Yu L–C, Broadberry RE, Yang Y–H, Chen Y–H, Lin M: Heterogeneity of the Secretor α(1,2)fucosyltransferase gene among Lewis (a+b+) non–secretors. Biochem Biophys Res Commun1996;222:390–394.
14.
Fraser RH, Allen EK, Inglis G, Munro AC, Mackie A, Mitchel R: Production and immunochemical characterization of mouse monoclonal antibodies to human Lewis a blood group structure. Exp Clin Immunogenet 1984;1:145–151.
15.
Fraser RH, Allan EK, Murphy MT, Inglis G, Mitchel R: Monoclonal anti–Lea and anti–Leb: Serological and immunochemical characterization (abstract). Proceedings of the 2nd International Workshop and Symposium on Monoclonal Antibodies against Human Red Blood Cells and Related Antigens, Lund 1990, p 73.
16.
Sambrook J, Fritsch EF, Maniatis T: Analysis and cloning of eukaryotic genomic DNA; in Molecular Cloning: A Laboratory Manual, 2. New York, Cold Spring Harbor Laboratory, 1989, vol 2, pp 9.16–9.19.
17.
Henry S, Simpson LA, Woodfield DG: The Le (a+b+) phenotype in Polynesians. Hum Hered 1988;38:111–116.
18.
Henry S, Mollicone R, Lowe JB, Samuelsson B, Larson G: A second nonsecretor allele of the blood group α(1,2)fucosyltransferase gene (FUT2). Vox Sang 1996;70:21–25.
19.
Koda Y, Soejima M, Liu Y, Kimura H: Molecular basis for Secretor type α(1,2)–fucosyltransferase gene deficiency in a Japanese population: A fusion gene generated by unequal crossover responsible for the enzyme deficiency. Am J Hum Genet 1996;59:343–350.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.